Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function

Affiliations

• ¹ Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany.
• ² Mousepathology, Animal Experimental Unit, Helmholtz-Center for Infection Research, Braunschweig, Germany.
• ³ Department of Transfusion Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany.
• ⁴ Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Medical Center, Magdeburg, Germany.
• ⁵ Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Medical Center, Magdeburg, Germany Department of Immune Control, Helmholtz Center for Infection Research, Braunschwei, Germany.
• ⁶ Department of Experimental Pediatrics, Otto-von-Guericke University Medical Center, Magdeburg, Germany.
• ⁷ Institute of Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Medical Center, Magdeburg, Germany.
• ⁸ Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany German Cancer Research Center (DKFZ), Division of Epigenomics and Cancer Risk Factors, Heidelberg, Germany.
• ⁹ Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany [email protected].